NCT00667641View on ClinicalTrials.gov

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Breast CancerColorectal CancerHead and Neck CancerLung CancerMelanoma (Skin)Ovarian CancerPancreatic CancerProstate CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

bortezomib

Starting dose level 0.70mg/m2

DRUG

paclitaxel

Starting dose level 40mg/m2

Trial Locations (1)

08903

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Medicine and Dentistry of New Jersey

OTHER

NCT00667641 - Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | Biotech Hunter | Biotech Hunter